Abstract: An air cooled machine is formed with a housing and a plurality of heat rejecting fins with a heat pipe system disposed therein. The heat pipe system includes a primary passageway and a plurality of leg passageways extending through the housing and into each fin. A working fluid is disposed within the heat pipe system and is operable to receive heat from a heat source, change material phase at a threshold temperature and transfer the heat through the fins to a surrounding atmosphere.

Abstract: An aircraft propulsion system includes a hybrid-electric power plant for delivering power to an air mover for propelling an aircraft. The hybrid-electric power plant includes a heat engine operatively connected to a first air mover, and an electric motor operatively connected to a second air mover. The second air mover is positioned on a wing of the aircraft outboard from the heat engine. A method for reducing trailing vortices includes powering a first air mover of an aircraft with a heat engine during a take-off stage, a climb stage, a cruise-stage and/or a descent stage. The method includes powering a second air mover of the aircraft with an electrical motor during the take-off stage and/or the climb stage. The method includes freewheeling the second air mover during the cruise stage and/or the descent stage to generate mechanical energy and reduce wing tip vortices.

Abstract: A non-enzymatic debridement agent that is less expensive, less cytotoxic, and more effective than enzymatic and sharp surgical debridement of eschar material. The non-enzymatic debridement agent is based on a formulation of detergent with a high critical micelle concentration and a denaturing agent along with an optional optimized buffer. The non-enzymatic wound debriding agent is able to dissolve eschar material in under one week. The buffer or ointment may contain an optimized pH, salt concentration, reducing agent, and other components that aid in the debridement of eschar material from chronic wounds and burn wounds. The non-enzymatic debridement agent can be formulated as an ointment, liquid rinse under pressure, and/or as a combination product with an advanced wound dressing that can act as a sink to remove the solubilized eschar material from the surface of the wound to assist in the debridment and proper healing of wounds.

Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of bacteria, for example, wound bacteria in a sample, by contacting a sample with a peptide substrate derived from the modification of the reactive site loop (RSL) domain of the ?1-proteinase inhibitor. In the current invention, we have demonstrated that these peptide substrates without the alpha 1 protein can be efficiently used as peptide substrates. The modification or the absence of modification of this peptide substrate by the enzyme produced and/or secreted by the bacteria, can serve as an indicator for the presence or absence of the bacteria in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.

Abstract: Described herein is a substrate comprising at least one colorimetric component attached to a peptide, as well as methods for detecting a modification of said substrate. Also described are methods of detecting the presence or absence of a protein, for example, a protein produced by a microorganism, by contacting a substrate with a sample. If the sample contains the protein of interest, the substrate is modified and a visible color change results, indicating the presence or absence of the protein in the sample. The present invention also features biosensors and kits for detecting the presence or absence of microorganisms and/or proteins in a sample.

Abstract: Described herein are zymogens, methods of use for zymogens, and devices that incorporate zymogens. The zymogens include a substrate and an enzyme. The substrate can inhibit the enzyme and is a target for a protein produced by a microorganism. When the substrate is modified by a protein produced by a microorganism, the enzyme is activated. The zymogens can be used to amplify detection assays.

Abstract: Described herein are substrates, methods, articles, and kits that are useful for detecting a condition in a female mammal. The substrates interact with one or more proteins (e.g., an enzyme) produced by a microorganism or the female animal. The substrates are labelled in order to produce a visible signal (e.g., a fluorescent glow and/or a visible change in color or hue) when modified by a protein produced by a microorganism of interest. The visible signal is used to assess a condition in the female mammal.

Abstract: Described herein are zymogens, methods of use for zymogens, and devices that incorporate zymogens. The zymogens include a substrate and an enzyme. The substrate can inhibit the enzyme and is a target for a protein produced by a microorganism. When the substrate is modified by a protein produced by a microorganism, the enzyme is activated. The zymogens can be used to amplify detection assays.

Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.

Abstract: Described herein are methods of detecting an infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.

Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with a cationic anti-microbial peptide that is degradable by an enzyme produced and/or secreted by a microorganism, and detecting degradation or the absence of degradation of the peptide, as an indicator of the presence or absence of the enzyme in the sample, and thus indicative of the presence or absence of a microorganism in the sample. The present invention also features a biosensor for detecting the presence or absence of a microorganism in a sample.

Abstract: The present invention features methods of increasing cell or tissue viability by administering to the cell or tissue a protective protein. The invention also features methods of treating a condition characterized by cell or tissue damage in a subject by administering to the subject a protective protein. Also included are chimeric proteins as well as methods of inhibiting proteolysis of a cationic antimicrobial peptide in a cell or tissue including contacting the cell or tissue with a protective protein, chimeric protein that includes the protective protein, or a biologically active fragment, variant, or derivative thereof.

Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.

Abstract: A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific protease that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the protease that is a marker for the presence of a specific prokaryotic microbe by cleaving a substrate when the protease is present; and signaling the presence of that protease when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example Listeria monocytogenes and that is substrate specific.

Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of microorganisms, for example, wound pathogens in a sample, by contacting a sample with an enzyme produced and/or secreted by the bacteria, and detecting modification or the absence of modification of the substrate, as an indicator of the presence or absence of the enzyme in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.

Abstract: Thymosin beta-4 (TB4), Thymosin beta-9 (TB9), and acyl-CoA binding protein (ACBP) are two proteins that possess the ability to bind lead in human tissue. These two proteins have a high affinity lead-binding region with a dissociation constant (Kd) of about 10?9 M that allows for a strong interaction between the metal and the protein. These proteins and their analogs and lead-binding fragments can be used to detect and remove lead from various media.